Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Molecular Diagnostics Market to Grow from USD 19.48 Billion in 2025 to USD 30.74 Billion by 2030, at a CAGR of 9.6% - MarketsandMarkets™

globenewswire.com
DHR Danaher is identified as a leading player in the molecular diagnostics market, benefiting from its strong US presence, international expansion, product innovation, R&D investments, regulatory approvals, partnerships, and acquisitions. The company is well-positioned to capitalize on the growing demand for precise and timely molecular testing. ILMN Illumina is a prominent player in sequencing-based molecular diagnostics, with a strong NGS portfolio. Its applications in oncology, reproductive health, rare genetic disorders, and infectious disease testing position it well within the growing molecular diagnostics market. HOLX Hologic, Inc. is listed as one of the top five players in the molecular diagnostics market, contributing to market growth through technological innovation, regulatory clearances, global market expansion, and a broad diagnostic portfolio. This indicates a positive outlook for the company within this sector. TMO Thermo Fisher Scientific Inc. is mentioned as a prominent player in the molecular diagnostics market. While not given specific positive or negative commentary, its inclusion suggests it is a significant entity within this growing industry. ABT Abbott is listed as a prominent player in the molecular diagnostics market. The article does not provide specific sentiment but its inclusion as a key company suggests relevance to the market's growth. RIVN Revvity, Inc. is mentioned as a prominent player in the molecular diagnostics market. The article does not provide specific sentiment but its inclusion as a key company suggests relevance to the market's growth. DGX While not explicitly mentioned by name, diagnostic laboratories are highlighted as the largest end-user segment in the molecular diagnostics market. Companies like Quest Diagnostics, which operate in this space, are likely to benefit from the market's growth. MYGN Myriad Genetics, Inc. is listed as a prominent player in the molecular diagnostics market. The article does not provide specific sentiment but its inclusion as a key company suggests relevance to the market's growth. EXAS Exact Sciences Corporation is listed as a prominent player in the molecular diagnostics market. The article does not provide specific sentiment but its inclusion as a key company suggests relevance to the market's growth. BDX Becton, Dickinson and Company is listed as a prominent player in the molecular diagnostics market. The article does not provide specific sentiment but its inclusion as a key company suggests relevance to the market's growth. BRKR Bruker is listed as a prominent player in the molecular diagnostics market. The article does not provide specific sentiment but its inclusion as a key company suggests relevance to the market's growth.

Molecular Diagnostics Market to Grow from USD 19.48 Billion in 2025 to USD 30.74 Billion by 2030, at a CAGR of 9.6% - MarketsandMarkets™ Delray Beach, FLs, Aug. 19, 2026 (GLOBE NEWSWIRE) -- MarketsandMarkets™ projects the global molecular diagnostics market will grow from USD 19.48 billion in 2025 to USD 30.74 billion by 2030, at a CAGR of 9.6% during the forecast period. Market growth is fueled by the increasing prevalence of infectious diseases, cancer, and genetic disorders, rising government and private-sector investment in research and development, growing emphasis on personalized medicine, and technological advances in PCR, next-generation sequencing (NGS), and isothermal amplification.

Get PDF Brochure - Market Data & Segmentation: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=833

Key Market Highlights

Why This Market Matters

Molecular diagnostics is becoming increasingly important as healthcare systems seek faster, more accurate, and more targeted approaches to disease detection and monitoring. The rising prevalence of infectious diseases, cancer, and genetic disorders is increasing demand for molecular testing, while growing awareness of early disease detection and preventive healthcare is supporting broader adoption. Advances in PCR, NGS, and isothermal amplification are improving test speed, sensitivity, and versatility, while portable and rapid-turnaround platforms are helping smaller healthcare facilities incorporate molecular testing into routine workflows.

Market Overview

The molecular diagnostics market is witnessing sustained growth as hospitals, diagnostic laboratories, and clinics expand their use of advanced molecular testing technologies. Government funding, targeted R&D programs, and public-private partnerships are supporting the development of next-generation diagnostic platforms, including digital PCR, multiplex assays, and sequencing-based solutions. At the same time, expanding healthcare infrastructure and rising healthcare expenditure in emerging economies are creating new opportunities for molecular diagnostic manufacturers and service providers.

Analyst Perspective

The molecular diagnostics industry is moving toward faster, more accessible, and increasingly comprehensive testing workflows. The continued development of high-throughput platforms, automation-compatible reagents, multiplex assays, and sequencing technologies is helping laboratories improve efficiency and diagnostic accuracy. Companies that combine strong innovation pipelines with regulatory capabilities, strategic partnerships, product launches, and expansion into emerging markets are positioned to strengthen their competitive standing as demand for precise and timely molecular testing increases.

Speak to Our Analyst - Get Custom Insights:

https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=833

Segment Analysis

By product & service, reagents & kits accounted for the largest market share in 2024, supported by their broad applicability across PCR, NGS, and isothermal amplification workflows. High testing volumes, recurring consumption, and continued development of ready-to-use and automation-compatible formulations are supporting demand from hospitals, clinics, and diagnostic laboratories.

By end user, diagnostic laboratories accounted for the largest market in 2024. Increasing testing volumes for infectious diseases, cancer, and genetic disorders, combined with the need for advanced technical capabilities and high-throughput processing, is supporting the segment. Healthcare providers also increasingly outsource complex molecular testing to specialized laboratories because of their advanced instrumentation, trained personnel, and ability to adopt innovative assays efficiently.

Regional Analysis

North America accounted for the largest share of the molecular diagnostics market in 2024, supported by advanced healthcare infrastructure, robust laboratory networks, strong research capabilities, and the presence of leading molecular diagnostics companies. High adoption of innovative technologies, ongoing R&D investment, and supportive regulatory policies are further contributing to regional leadership. Asia Pacific is expected to register the highest CAGR during the forecast period, driven by increasing healthcare expenditure, rapid expansion of medical infrastructure, growing patient populations, and rising investments in diagnostic technologies.

Key Industry Trends

Competitive Landscape

The competitive landscape of the molecular diagnostics market is led by established global companies including Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (US), bioMérieux (France), and Hologic, Inc. (US), along with other prominent players such as QIAGEN N.V., Thermo Fisher Scientific Inc., Siemens Healthineers AG, Abbott, Revvity, Inc., Grifols S.A., QuidelOrtho Corporation, DiaSorin S.p.A., Becton, Dickinson and Company, Myriad Genetics, Inc., Agilent Technologies, Inc., Exact Sciences Corporation, MDxHealth, TBG Diagnostics Limited, Amoy Diagnostics Co., Ltd., Biocartis, Bruker, Genetic Signatures Ltd., Unijogen Oy, Vela Diagnostics, Molbio Diagnostics Limited, Savyon Diagnostics, and geneOmbio Technologies.

Danaher remains a leading player, supported by its strong US presence, international expansion strategy, product innovation, R&D investments, regulatory approvals, partnerships, and acquisitions. F. Hoffmann-La Roche Ltd. maintains a significant position through its broad geographic reach, extensive distribution network, and strategic acquisitions that strengthen its technology portfolio. Illumina is prominent in sequencing-based molecular diagnostics, with a strong NGS portfolio and applications spanning oncology, reproductive health, rare genetic disorders, and infectious disease testing.

The top five players in the molecular diagnostics market are Danaher Corporation, F. Hoffmann-La Roche Ltd., Illumina, Inc., bioMérieux, and Hologic, Inc. Together, these companies contribute to market growth through technological innovation, regulatory clearances, global market expansion, and broad diagnostic portfolios.

Related Reports

In Vitro Diagnostics Market

Next-generation Sequencing Market